Pages that link to "Q34991112"
The following pages link to Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. (Q34991112):
Displaying 18 items.
- Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection (Q26775082) (← links)
- A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine (Q26830360) (← links)
- The evolution of poxvirus vaccines (Q26995905) (← links)
- Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates (Q35914311) (← links)
- Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques (Q35989484) (← links)
- Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens (Q36736400) (← links)
- Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses. (Q36947039) (← links)
- A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles (Q40220988) (← links)
- HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci (Q40339467) (← links)
- Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo (Q47549105) (← links)
- Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost (Q59351003) (← links)
- Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC (Q59351008) (← links)
- Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors (Q59360867) (← links)
- A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses (Q64252630) (← links)
- M918: A Novel Cell Penetrating Peptide for Effective Delivery of HIV-1 Nef and Hsp20-Nef Proteins into Eukaryotic Cell Lines. (Q64966698) (← links)
- Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial (Q90637089) (← links)
- Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector (Q92288781) (← links)
- Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses (Q92538912) (← links)